<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>The Liver Meeting</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Bluejay way: Positive phase II data for treating hepatitis D</title>
      <description>
        <![CDATA[Bluejay Therapeutics Inc.’s lead compound, the fully human monoclonal antibody brelovitug (BJT-778), produced positive virologic response data in the company’s phase II study of chronic hepatitis D virus, a condition with no approved treatment in the U.S.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726111</guid>
      <pubDate>Tue, 11 Nov 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726111-bluejay-way-positive-phase-ii-data-for-treating-hepatitis-d</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-anatomy-with-virus.webp?t=1717618903" type="image/jpeg" medium="image" fileSize="305581">
        <media:title type="plain">Liver anatomy with virus</media:title>
      </media:content>
    </item>
    <item>
      <title>MASH prospects from Rivus, Metavia show promise in phase II</title>
      <description>
        <![CDATA[Phase II data being presented at the American Association for the Study of Liver Diseases annual meeting indicate drug development in the field of metabolic dysfunction-associated steatohepatitis (MASH) is making steady progress.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725887</guid>
      <pubDate>Fri, 07 Nov 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725887-mash-prospects-from-rivus-metavia-show-promise-in-phase-ii</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-on-digital-lens.webp?t=1709588066" type="image/jpeg" medium="image" fileSize="175206">
        <media:title type="plain">Liver over digital lens background</media:title>
      </media:content>
    </item>
    <item>
      <title>The Liver Meeting: A mashup of MASH data</title>
      <description>
        <![CDATA[Advertisements for Rezdiffra (resmetirom, Madrigal Pharmaceuticals Inc.), which was approved by the U.S. FDA in March 2024, adorned the lobby of The Liver Meeting 2024 being held at the San Diego Convention Center as well as the trolley stop across the street and other areas that doctors attending the meeting might be swayed. But inside the ballrooms of the convention center, companies were making presentations of data from clinical trials testing their drugs in patients with metabolic dysfunction-associated steatohepatitis (MASH) in hopes of potentially competing with Rezdiffra in a few years.]]>
      </description>
      <guid>http://www.bioworld.com/articles/714647</guid>
      <pubDate>Tue, 19 Nov 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/714647-the-liver-meeting-a-mashup-of-mash-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-7-7.webp?t=1657229334" type="image/png" medium="image" fileSize="759348">
        <media:title type="plain">Liver </media:title>
      </media:content>
    </item>
    <item>
      <title>The Liver Meeting: A cure for hepatitis B’s low-hanging fruit</title>
      <description>
        <![CDATA[Patients infected with hepatitis C have had the ability to rid their livers of the virus for some time, while patients with chronic hepatitis B virus infection have been required to take medications for the rest of their lives in the hopes of just dampening damage to the liver caused by the virus. But, at The Liver Meeting 2024, Arbutus presented data from the phase IIa Im-prove study suggesting a cure might be on its way with its DNAi drug, which binds to the viral mRNA promoting its cutting, leading to loss of translation of the viral proteins.]]>
      </description>
      <guid>http://www.bioworld.com/articles/714591</guid>
      <pubDate>Mon, 18 Nov 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/714591-the-liver-meeting-a-cure-for-hepatitis-bs-low-hanging-fruit</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Liver-infection-with-hepatitis-viruses.webp?t=1680533897" type="image/png" medium="image" fileSize="1333192">
        <media:title type="plain">Illustration of liver infection</media:title>
      </media:content>
    </item>
    <item>
      <title>At AASLD 2022, polygenic risk score subtypes in NAFLD</title>
      <description>
        <![CDATA[Modern molecular techniques have progressed to the point where sequencing can seem almost quaint. At the Basic Science Symposium of the American Association for the Study of Liver Diseases 2022 meeting (AASLD 2022), new techniques were on full display, with sessions devoted to epigenetics, microbiome analysis and spatial transcriptomics. But the first session was still on genetic variants in all their forms – rare variants, common variants and nongermline mutations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/691349</guid>
      <pubDate>Tue, 08 Nov 2022 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/691349-at-aasld-2022-polygenic-risk-score-subtypes-in-nafld</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/AASLD-Nov-8---Hero.webp?t=1667926551" type="image/png" medium="image" fileSize="681269">
        <media:title type="plain">Triglyceride fat accumulated inside liver cells</media:title>
        <media:description type="plain">3D illustration and photomicrograph of triglyceride fat accumulated inside liver cells. Credit: Kateryna Kon</media:description>
      </media:content>
    </item>
    <item>
      <title>At AASLD 2022, polygenic risk score subtypes NAFLD</title>
      <description>
        <![CDATA[Modern molecular techniques have progressed to the point where sequencing can seem almost quaint. At the Basic Science Symposium of The Liver Meeting 2022, new techniques were on full display, with sessions devoted to epigenetics, microbiome analysis and spatial transcriptomics. But the first session was still on genetic variants in all their forms – rare variants, common variants and non-germline mutations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/691345</guid>
      <pubDate>Mon, 07 Nov 2022 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/691345-at-aasld-2022-polygenic-risk-score-subtypes-nafld</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-illustration.webp?t=1613674462" type="image/png" medium="image" fileSize="432664">
        <media:title type="plain">Liver illustration</media:title>
        <media:description type="plain">Credit: Georgia State University</media:description>
      </media:content>
    </item>
    <item>
      <title>AASLD 2022: Robust microbiome engineering enables mechanistic insights</title>
      <description>
        <![CDATA[High hopes rest on manipulating the gut microbiome in order to treat a multitude of disorders. Clinical validation for the idea has come from the success of fecal microbiome transplants to treat chronic <em>Clostridium difficile</em> infections. Such transplants are in clinical trials to treat other gastrointestinal disorders, and more targeted methods to manipulate the microbiome are being developed as well, not just for infections, but in a multitude of other indications. Targeting the gut microbiome may turn into a way to alleviate inflammatory bowel disease, food allergies, and even psychiatric conditions.]]>
      </description>
      <guid>http://www.bioworld.com/articles/691302</guid>
      <pubDate>Mon, 07 Nov 2022 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/691302-aasld-2022-robust-microbiome-engineering-enables-mechanistic-insights</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NIH-NIAID-Scanning-electron-micrograph-of-Escherichia-coli.webp?t=1667837128" type="image/png" medium="image" fileSize="2031153">
        <media:title type="plain">Colorized scanning electron micrograph of E. coli bacteria.</media:title>
        <media:description type="plain">Escherichia coli bacteria. Credit: National Institute of Allergy and Infectious Diseases, NIH
</media:description>
      </media:content>
    </item>
    <item>
      <title>AASLD meeting: Cholangiocytes can induce liver regeneration</title>
      <description>
        <![CDATA[In contrast to most adult mammalian tissues, the liver can regenerate itself to an impressive degree. That regeneration is critical to survival – as a key digestive organ, the liver deals with all sorts of toxins, from rotten-ish food in the wild to alcohol in more cultured settings.]]>
      </description>
      <guid>http://www.bioworld.com/articles/513404</guid>
      <pubDate>Tue, 16 Nov 2021 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/513404-aasld-meeting-cholangiocytes-can-induce-liver-regeneration</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-illustration.webp?t=1613674462" type="image/png" medium="image" fileSize="432664">
        <media:title type="plain">Liver illustration</media:title>
        <media:description type="plain">Credit: Georgia State University</media:description>
      </media:content>
    </item>
    <item>
      <title>Conference data for Nov. 15, 2021: AASLD</title>
      <description>
        <![CDATA[New and updated preclinical and clinical data presented by biopharma firms at The Liver Meeting of the American Association for the Study of Liver Diseases, including: 89bio, Akero, Cymabay, Intercept, Protagonist, Sagimet, Surrozen, Versantis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/513376</guid>
      <pubDate>Mon, 15 Nov 2021 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/513376-conference-data-for-nov-15-2021-aasld</link>
    </item>
  </channel>
</rss>
